Publications by authors named "K E Clegg"
Article Synopsis
- - The CARE-FH clinical trial aimed to enhance screening for Familial Hypercholesterolemia (FH) in primary care settings by incorporating feedback from healthcare professionals involved in patient care.
- - The trial identified that FH screening was infrequent, often occurring only post-cardiovascular events, but found that healthcare providers were generally open to implementing screening with some adjustments.
- - Barriers like limited time during patient visits and lack of knowledge were noted, but effective guidance and new treatments showed promise as facilitators for improving FH screening and care initiation.
CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP from an enhancer subset marked by strong MYB occupancy and high H3K27 acetylation, with downregulation of the subordinate oncogenic network and redistribution to sites close to differentiation genes. In myeloma cells, CCS1477 induces eviction of EP300/CBP from FGFR3, the target of the common (4; 14) translocation, with redistribution away from IRF4-occupied sites to TCF3/E2A-occupied sites.
View Article and Find Full Text PDFBackground: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States. Case-based learning using electronic delivery of the modules can educate clinicians and improve translation of evidence-based guidelines into practice for high-risk ASCVD patients.
Objective: To develop and optimize module design, content, and usability of e-learning modules to teach clinicians evidence-based management in accordance with multi-society guidelines for high-risk ASCVD patients that will be implemented and evaluated in U.
Purpose Of Review: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS).
Recent Findings: Multiple organizations around the world have produced guidance documents to aid clinicians on managing statin intolerance. A common theme resides among all the guidance documents that most patients can tolerate statins.
Article Synopsis
- Telehealth services have grown significantly during the COVID-19 pandemic, particularly for managing chronic conditions like lipid issues, yet their precise impact on lipid management practices is not well understood.
- A research review identified 55 relevant articles, primarily randomized trials, showing that telehealth generally had positive to neutral effects on lipid management, supported by easier care integration and patient-centered approaches.
- Barriers to effective telehealth include technological issues, costs, patient adherence challenges, and inconsistencies in clinician practices, highlighting the need for more research to assess the long-term viability of telehealth for lipid management.